Plain-English translation of NCT06111638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing BBM-H803, a new type of treatment called gene therapy for people with severe hemophilia A. The medication uses a modified virus to deliver instructions that help your body make its own clotting factor (Factor VIII), which people with hemophilia A lack. Researchers want to see if this single injection can safely improve your ability to clot blood and reduce bleeding episodes.
People with severe hemophilia A currently need regular infusions of clotting factor to prevent dangerous bleeding. This medication aims to offer a longer-lasting solution by helping the body produce its own clotting factor, potentially reducing the burden of frequent treatments.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the medication at the study center. After that, you will have follow-up visits and blood tests over a 52-week period to monitor your safety and how well the treatment works. The study team will check your clotting ability, look for any side effects, and track whether you have fewer bleeding episodes. You cannot have major surgery during the study, and you'll need to avoid certain medications, herbal supplements, and alcohol during this time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China